International Journal of Endocrinology

Research Article

Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism

Table 4

Imaging modalities used for the diagnostic procedure either for primary sites and metastasis.


	Oesophagus	Gastric	Pancreas	Appendiceal	Duodenum	Jejunum-ileum	Colon	Rectum	UPT	Positive/total exams

Upper endoscopy	3/3 (100.0)	27/30 (90.0)	—	—	17/19 (89.5)	—	—	—	1/4 (25.0)	48/56 (85.7)
Echoendoscopy	—	7/13 (53.8)	25/28 (89.3)	—	6/6 (100.0)	—	—	10/10 (100.0)	—	48/57 (84.2)
Video capsule	—	—	—	—	—	8/9 (88.9)	—	—	—	8/9 (88.9)
Double balloon	—	—	—	—	—	1/1 (100.0)	—	—	—	1/1 (100.0)
Colonoscopy	—	—	—	—	—	12/33 (36.4)	12/12 (100.0)	21/22 (95.5)	—	45/67 (67.2)
Entero-CT	—	—	—	—	—	4/4 (100.0)	—	—	—	4/4 (100.0)
Entero-MRI	—	—	—	—	—	11/11 (100.0)	1/1 (100.0)	—	—	12/12 (100.0)
US scan	—	5/12 (41.7)	33/41 (80.5)	1/4 (25.0)	2/2 (100.0)	23/27 (85.2)	1/2 (50.0)	0/3 (0.0)	1/1 (100.0)	66/92 (71.7)
CT scan	3/3 (100)	10/22 (45.5)	71/77 (92.2)	4/11 (36.4)	13/17 (76.5)	52/62 (83.9)	13/15 (86.7)	9/20 (45.0)	6/6 (100.0)	181/233 (77.7)
MRI	—	0/3 (0.0)	38/44 (86.4)	1/1 (100.0)	5/5 (100.0)	11/13 (84.6)	2/4 (50.0)	4/9 (44.4)	2/2 (100.0)	63/81 (77.8)
¹¹¹In-pentetreotide^‡	—	6/17 (35.3)	26/36 (72.2)	2/6 (33.3)	8/12 (66.7)	25/30 (83.3)	5/8 (62.5)	2/9 (22.2)	3/3 (100.0)	77/121 (63.6)
⁶⁸Ga-PET-SRP	—	5/12 (41.7)	26/31 (83.9)	2/5 (40%)	1/2 (50.0)	32/34 (94.1)	2/2 (100.0)	5/11 (45.5)	2/2 (100.0)	75/99 (75.8)
PET-FDG	2/2 (100.0)	0/5 (0.0)	10/17 (58.8)	0/1 (0.0)	1/1 (100.0)	2/4 (50.0)	3/5 (60.0)	—	1/1 (100)	19/36 (52.8)

^‡Octreoscan®; UPT: unknown primary tumour; CT: computed tomography; MRI: magnetic resonance imaging; PET-FDG: positron emission tomography-(¹⁸F) fluorodeoxyglucose.